Article Text

Download PDFPDF
Langerhans cell histiocytosis of the female genital tract: A literature review
  1. A. J. MONTERO*,
  2. C.M. DÍAZ-MONTERO,
  3. A. MALPICA,
  4. P.T. RAMIREZ§ and
  5. J.J. KAVANAGH
  1. * Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  2. †Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  3. ‡Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  4. §Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  5. ¶Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  1. Address correspondence and reprint requests to: John. J. Kavanagh, MD, Department of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard Box 401, Houston, TX 77030–4009. Email: jkavanag{at}mdanderson.org.

Abstract

Langerhans cell histiocytosis (LCH) is a rare malignant disease involving the accumulation of a monoclonal proliferation of cells in various organs, that phenotypically resemble Langerhans cells (LC). LCH is not merely a hyperplasia of LC, as it typically affects organs that are outside of their normal physiologic distribution. Normal Langerhans cells are bone marrow-derived dendritic cells that populate the epidermis and are distinguished by the presence of Birbeck granules and cell surface protein CD1a. LC act as sentinels; they recognize, internalize, and process antigens encountered in the skin. Upon encountering an antigen, LC become activated with subsequent maturation and induction of their migratory capacity. Langerhans cells in patients with LCH are aberrant and profoundly differ from normal LC. The clinical spectrum of LCH is quite diverse; multiple organs can be affected. “Pure” genital Langerhans cell histiocytosis is a rare presentation, with only 12 previously reported cases. Due to the rarity of this disease, treatment of genital LCH is still very diverse. No modality is proven to be superior in improving patient outcome, and relapses frequently occur after surgery. Dramatic responses of cutaneous and ano-genital lesions to thalidomide and interferons have been reported. We advocate the use of immuno-modulating agents in LCH of the female genital tract first, rather than surgery.

  • dendritic cell
  • female genital tract
  • histiocytosis
  • LCH
  • thalidomide

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.